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A b s t r a c t  
Pain is commonly associated with depression. Both pain and depression share common biological 
pathways and neurotransmitters, which has implications for the treatment of both disorders. A drug 
that could ameliorate both pain and depression could be beneficial in the development of new 
therapeutics in the management of disorders associated with pain/depression dyad. Alterations in 
the neurotransmitters namely, serotonin and norepinephrine in the central nervous system (CNS) 
have been implicated in the pathophysiology of pain and depression. Serotonin and norepinephrine 
reuptake inhibitors (SNRIs) have been implicated as a novel therapeutic target for a wide range of 
biological functions, including pain, anxiety and depression. 2-benzoxazolinone (2-BOA) from the 
mangrove Acanthus ilicifolius and its derivatives have been reported for its analgesic and 
antidepressant activities. In the present work, docking studies were done on the crystal structure of 
human transporters of serotonin (hSERT) and on homology modeled human transporters of 
norepinephrine (hNET) as therapeutic targets of depression and pain related disorders using 2-BOA 
and its derivatives as potential candidates. A homology model for hNET was constructed using 
MODELLER and validated. Further docking studies were done on hSERT and hNET using 2-BOA 
and its structural analogs. The result of the study proposes the possible potential candidate among 
2-BOA derivatives that may be further developed as a therapeutic lead compound for use in 
disorders associated with depression and pain. 
Keywords: 2-Benzoxazolinone, Serotonin transporter, Norepinephrine transporter, Acanthus 
ilicifolius, Genetic Optimization for Ligand Docking, hNET/hSERT.
Introduction 
Norepinephrine and Serotonin are strongly associated with 
depression [1-6] and also modulate pain sensitivity via the 
descending pain pathway [7-10]. Serotonergic and noradrenergic 
neurons are localized in the Pons and medulla (raphe nuclei), and 
their axons project to brain regions such as the limbic system, the 
cerebral cortex and hypothalamus [11]. Norepinephrine transporter 
(NET) and Serotonin transporter (SERT) are integral membrane 
proteins belong to the large neurotransmitter: sodium symporter 
(NSS) family of transporters and they regulate monoamine 
concentrations at neuronal synapses by carrying monoamines 
across neuronal membranes into presynaptic nerve cells, using an 
inwardly directed sodium gradient as an energy source  [4, 11-12]. 
Selective serotonin and norepinephrine reuptake transporter 
inhibitors (SNRIs) are the pharmacological targets in clinical 
conditions associated with pain/depression dyad [12]. A number of 
antidepressant medications have demonstrated efficacy in treating 
chronic pain disorders [13-14]. Recent studies reported that 
compounds with dual activity at both NET and SERT are effective 
analgesics [15]. SNRIs such as duloxetine [16] and milnacipran [3, 
17] are approved for the treatment of chronic pain syndromes such 
as painful diabetic peripheral neuropathy, chronic musculoskeletal 
pain and/or fibromyalgia [17-20]. According to various medical 
literatures, several adverse reactions are known to be associated 
with these conventional SNRIs, thereby limiting the widespread 
application of these agents.  
2-Benzoxazolinone (2-BOA) is a bioactive compound isolated from 
a mangrove plant Acanthus ilicifolius [21]. 2-BOA and its structural 
analogs have been investigated widely for their analgesic, 
anticonvulsant, hypnotic, skeletal muscle relaxant and CNS 
depressant activities [22-24]. The present study investigated the 
interactions of 2-BOA and its structural analogs with active site 
residues of human serotonin transporter (hSERT) and 
norepinephrine transporter (hNET) proteins. Molecular docking is 
basically a conformational sampling procedure in which hundreds 
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of molecules can be screened to identify plausible binder by 
docking them into the predicted binding pocket on the target 
protein. This paper reports the docking studies and the binding 
properties of BOA and its analogs towards hSERT and hNET 
membrane receptor proteins. 
Materials and Methods  
Homology modeling and structure validation 
The protein crystal structure of hNET was unavailable and 
therefore homology modeling is the alternative choice to construct 
a reasonable three dimensional (3D) model of the target. The 
protein sequence of hNET was obtained from the Uniprot database 
[25] [Accession no: P23975] using the Gapped-BLAST [26]. 
Through PDB BLAST the crystal structure of dopamine transporter 
(PDB code: 4M48) with 2.95Å resolution with 60% sequence 
identity with hNET was identified as a template. Thus, Dopamine 
transporter chosen as a suitable template to construct a 3D model 
of the target protein hNET using MODELLER 9.11 [27]. 
Based on the template structure and target sequence alignment, 
10 structural models were constructed using MODELLER. The 
initial models were assessed using Z-DOPE, a normalized atomic 
distance-dependent statistical potential based on known protein 
structures [28].  The constructed 3D model of hNET was refined 
and the model quality was validated using PROCHECK server [29]. 
PROCHECK analysis, which includes checks on chirality, dihedral 
angles, planarity, disulphide bonds, covalent geometry, non-
bonded interactions, stereo chemical parameters, main-chain 
hydrogen bonds, parameter comparisons, and residue-by-residue 
analysis. The backbone conformation of Phi and Psi angles for 
polypeptide was predicted using Ramachandran plot.  
Molecular docking protocol  
Ligand Preparation 
The 3D structure of 2-BOA, 6-Methyl-2-BOA, 6-hydroxy- 2-BOA, 6-
chloro-2-BOA, and 6-Bromo-2-BOA were obtained from NCBI 
PubChem compound [30]. Further the 3D structural conformations 
were optimized using Marvin Sketch (MarvinSketch V 5.2.6, 
ChemAxon Ltd, copyright 1998-2009.) Energy minimization of 
ligands was done using chimera software [31].   
Docking studies with hSERT and hNET 
The hSERT and hNET proteins were selected as depression and 
pain modulation drug target in the present study. The hSERT 
protein structure was obtained from the Research Collaboratory for 
Structural Bioinformatics (RCSB) protein data bank (PDB code: 
4IB4) with 2.7Å resolution [28, 32]. The crystallographic water 
molecules and co-crystallized ligands were identified and removed 
from the 3-dimensional (3D) atomic coordinate file and hydrogen 
atoms were added, and partial charges were assigned. 
Similarly, the optimized homology model of the human 
norepinephrine transporter (hNET) was considered for docking 
studies. Molecular docking studies were done using GOLD 
(Genetic Optimization for Ligand Docking) program version 5.1. 
GOLD is an automated docking program that employs a genetic 
algorithm to search the ligand conformational flexibility and partial 
proteinÊs active site flexibility [33]. Four different scoring functions, 
namely ChemPLP, GoldScore, ChemScore, and ASP (the Astex 
Statistical Potential) were employed, but among them GoldScore 
was identified as the suitable scoring function for both hSERT and 
hNET. In the case of hSERT, the ergotamine binding site was 
defined as the active site with 12 Å radius for docking, while in the 
case of docking the hNET homology model, the nortriptyline 
binding site as in the template structure (PDB code: 4M48) was 
considered as the active site within 12 Å for docking all the five 
BOA derivatives with 100% genetic algorithm (GA) using the 
Goldscore fitness function.  
The ranking of the compounds was based on the firstly ranked 
solution as well as the lowest energy conformation of the most 
populated cluster of the docking procedure. During the analysis, it 
was prioritized that the binding mode of BOA derivatives was 
compared with the binding mode of Ergotamine as reference for 
hSERT inhibitor. While in the case of hNET the binding of the 
inhibitor were based on the binding mode of nortriptyline as 
reference. As a validation step to determine the plausibility binding 
mode of the five BOA derivatives, docking study was also 
performed in AutoDock [34-35]. The automated molecular docking 
simulations were performed by Genetic Algorithm- Local Search 
(GA-LS) [33] with standard parameters. The compounds were 
ranked based on the docking energy. The compound with the 
highest affinity for the target proteins active site pattern with lowest 
docking energy was selected. Here, we examined the performance 
of this docking software to select the best compound without any 
bias. The interaction energy includes Vander Waals energy, 
electrostatic energy, as well as intermolecular hydrogen bonding 
was also considered for each binding mode and visualized and 
analyzed using PyMol software [36]. Finally, the five BOA 
derivatives top ranked binding modes in agreement with GOLD 
upon superimposition were considered as the reliable binding 
mode.  
Results and Discussion 
Homology based model of hNET was accomplished by 
MODELLER 9.11 [34] using the dopamine transporter homolog 
(PDB code: 4M48), with a resolution of 2.95 Å as a template. The 
sequence identity between the hNET and the template dopamine 
transporter was about 60%. The 3D structural model of hNET 
generated by homology modeling has been examined by their 
stereo-chemical quality using PROCHECK shows that in the 
Ramachandran plot phi/psi angles of 95.2% residues were in the 
most favored regions, 4.2% residues were in the additional allowed 
regions and 0.6% fell in the generously allowed regions; only 0.0% 
of residues were in the disallowed conformations (Figure 1a). This 
analysis confirmed that the quality of the modeled hNET (Figure 
1b) was almost in good state and reliable. 









Figure 1 - Ramachandran plot and homology model of hNET 
 (a) Ramachandran plot of hNET model depicts the red, yellow, pale yellow and white color shaded regions correspond to residues in most favored regions, 
residues in additional allowed regions, residues in generously allowed regions and residues in disallowed regions. (b) Shows the homology modeled structure of 
hNET in green and gray color cartoon. 
 
Binding mode of BOA derivatives in hSERT  
The BOA derivatives 1-5 were docked on the GOLD to reveal their 
inhibitory potential on hSERT. Further the docked binding mode of 
GOLD was validated through AutoDock (Figure 2a). The binding 
mode of BOA shows that the oxygen in the ring forms hydrogen 
bond with the NH of the Asn153 side chain, while the benzene ring 
forms hydrophobic interaction with Val148, Met424 and Ala145 
(Figure 2b). Likewise, in the binding mode of 6-Methyl-2-BOA the 
oxygen attached to the ring forms hydrogen bond with NH of 
Asn153. 
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Figure 2 - The 2-BOA derivatives binding mode in hSERT 
Binding mode a. Comparison of GOLD and AutoDock in yellow and magenta color respectively.  b. 2-BOA (magenta color) c. 6-Methoxy-2-BOA (green color), d. 
6-hydroxy-2-BOA (blue color), e. 6-chloro-2-BOA (orange color), f. 6-Bromo-2-BOA (yellow color). Key residues are only shown and the hydrogen bond 
interactions are represented by yellow dashed lines. The BOA derivatives are shown as sticks and key amino acids as lines.  
 
While the NH on the ring of the compound forms hydrogen bond 
with Ser420, while the benzene ring and the methyl group form 
hydrophobic interaction with Val148, Met424 and Ala145 as in 
Figure 2c. The plausible binding mode of 6-hydroxy- 2-BOA shows 
that the hydroxyl oxygen forms hydrogen bond with NH of Asn153, 
while rings forms hydrophobic interaction with Tyr152,Val148, 
Met424 and Ala145 (Figure 2d). While in 6-chloro-2-BOA the ring 
oxygen and oxygen group forms hydrogen bond with Asn153 NH 
and the compound ring forms hydrophobic interaction with Ala145, 
Val148 and Met424 as in Figure 2e. In the case of 6-Bromo-2-
BOA,  
the Val148, Met424 and Ala145 forms hydrophobic interaction with 
the hydrophobic part of the ring system, while the oxygen at the 
ring forms hydrogen bond with Asn153 (Figure 2f). 
Binding mode of BOA derivatives in hNET  
Docking study of the BOA derivatives with the hNET are reported 
below. The binding mode agreement between GOLD and 
AutoDock binding mode is shown in Figure 3a. 
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Figure 3 - The 2-BOA derivatives binding mode in hNET 
 Binding mode a. Comparison of GOLD and AutoDock in brown and blue color respectively.  b. 2-BOA (brown color) c. 6-Hydroxy-2-BOA (violet 
color). Key residues are only shown and the hydrogen bond interactions are represented by yellow dashed lines. The BOA derivatives are shown 
as sticks and key amino acids as lines.  
 
Among the five derivatives of BOA and 6-Hydroxy-2-BOA forms 
stable binding mode while 6-Methoxy-2-BOA, 6-Bromo-2-BOA and 
6-chloro-2-BOA were not able to produce stable binding 
conformation in both GOLD and AutoDock docking studies. 
Therefore the later derivatives were not considered as potential 
binders of hNET. The binding mode of benzoxazolinone shows that 
the NH group form hydrogen bond interaction with Thr140 and the 
aromatic part of the ring forms hydrophobic interaction with 
hydrophobic residues such as Val136, Phe217, Met218, Ala225, 
Phe340 and Phe341(Figure 3b). While in the case of 6-Hydroxy-2-
BOA the hydroxyl group forms hydrogen bond with Val136 main 
chain oxygen and with OH group of Thr140 side chain. While the 
compound ring is also stabilized by hydrophobic interaction with 
Val136, Phe217, Met218, Ala225, Phe340 and Phe341 (Figure 3c).  
The putative binding orientation of the most potent BOA derivatives 
in the active sites of hSERT and hNET has been demonstrated. 
The analysis of docking results allowed us to postulate their 
theoretical capability of being potential compounds. 
Conclusion 
Finally, the molecular docking strategy reveals the binding mode of 
the 2-BOA derivatives and the key moieties responsible for the 
activity. Both active and inactive compounds adopt a diverse 
interaction pattern. The binding pose is clearly demonstrated that 
both the hydrophilic moieties and hydrophobic groups of the 
derivatives were crucial for the interaction which may determine the 
biological activity profile. These results suggest that 2-BOA 
derivatives have great potential to be further developed as a 
therapeutic lead molecule for use in disorders associated with 
depression and pain. Finally, we expect that these results will 
contribute to the development of newer analgesic with fewer 
adverse side effects. 
Authors' contributions 
MS performed in silico work, analysis of in silico data and drafted 
the manuscript.  SAR participated in collecting the relevant 
literatures required for the study and manuscript. KKS and RT 
contributed to experiment design.  KKS involved in manuscript 
correction, formatting the manuscript and references as per 
authorÊs guidelines. TLK and SMZ provided the software analysis 
tools for in silico studies and interpretation of data. All the authors 
read and corrected the manuscript. 
Conflict of Interest 




[1]. Hanna MM, Eid NM, George RF and 
Safwat HM. Synthesis of some tropane 
derivatives of anticipated activity on the 
reuptake of norepinephrine and/or 
serotonin. Bioorg Med Chem. 2007; 
15(24): 7765-7772. 
[2].  Andersen J, Stuhr-Hansen N, 
Zachariassen L, Toubro S, Hansen SM, 
Eildal JN, Bond AD, Bogeso KP, Bang-
Andersen B, Kristensen AS and 
Stromgaard K. Molecular determinants 
for selective recognition of 




PAGE | 394 |
 
antidepressants in the human serotonin 
and norepinephrine transporters. Proc 
Natl Acad Sci U S A. 2011; 108(29): 
12137-12142. 
[3].  Vickers T, Dyck B, Tamiya J, Zhang M, 
Jovic F, Grey J, Fleck BA, Aparicio A, 
Johns M, Jin L, Tang H, Foster AC and 
Chen C. Studies on a series of 
milnacipran analogs containing a 
heteroaromatic group as potent 
norepinephrine and serotonin 
transporter inhibitors. Bioorg Med Chem 
Lett. 2008; 18 (11): 3230-3235. 
[4].  Nencetti S, Mazzoni MR, Ortore G, 
Lapucci A, Giuntini J, Orlandini E, Banti 
I, Nuti E, Lucacchini A, Giannaccini G 
and Rossello A. Synthesis, molecular 
docking and binding studies of selective 
serotonin transporter inhibitors. Eur J 
Med Chem. 2011; 46(3): 825-834. 
[5].  Kharkar PS, Reith ME and Dutta AK. 
Three-dimensional quantitative 
structure-activity relationship (3D QSAR) 
and pharmacophore elucidation of 
tetrahydropyran derivatives as serotonin 
and norepinephrine transporter 
inhibitors. J Comput Aided Mol Des. 
2008; 22 (1): 1-17. 
[6].  Manepalli S, Geffert LM, Surratt CK and 
Madura JD. Discovery of novel selective 
serotonin reuptake inhibitors through 
development of a protein-based 
pharmacophore. J Chem Inf Model. 
2011; 51(9): 2417-2426. 
[7].  Hall FS, Schwarzbaum JM, Perona MT, 
Templin JS, Caron MG, Lesch KP, 
Murphy DL and Uhl GR. A greater role 
for the norepinephrine transporter than 
the serotonin transporter in murine 
nociception. Neuroscience. 2011; 175: 
315-327. 
[8].  Games G and Hutchison A. Tapentadol-
ER for the treatment of diabetic 
peripheral neuropathy. Consult Pharm. 
2013; 28 (10): 672-675. 
[9].  Attal N. Pharmacological treatment of 
neuropathic pain in primary care. Rev 
Prat. 2013; 63 (6): 795-802. 
[10]. Fitzgerald KT and Bronstein AC. 
Selective serotonin reuptake inhibitor 
exposure. Top Companion Anim Med. 
2013; 28 (1): 13-17. 
[11]. Gabrielsen M, Sylte I, Dahl SG and 
Ravna AW. A short update on the 
structure of drug binding sites on 
neurotransmitter transporters.  BMC Res 
Notes. 2011; 4: 559. 
[12]. Whiteside GT, Dwyer JM, Harrison JE, 
Beyer CE, Cummons T, Manzino L, 
Mark L, Johnston GH, Strassle BW, 
Adedoyin A, Lu P, Piesla MJ, Pulicicchio 
CM, Erve JC, Platt BJ, Hughes ZA, 
Rogers KE, Deecher DC, Trybulski EJ, 
Kennedy JD, Zhang P and Leventhal L. 
WAY-318068: a novel, potent and 
selective noradrenaline re-uptake 
inhibitor with activity in rodent models of 
pain and depression. Br J Pharmacol. 
2010; 160 (5): 1105-1118. 
[13]. Van Orden LJ, Van Dyke PM, Saito DR, 
Church TJ, Chang R, Smith JA, Martin 
WJ, Jaw-Tsai S and Stangeland EL. A 
novel class of 3-(phenoxy-phenyl-
methyl)-pyrrolidines as potent and 
balanced norepinephrine and serotonin 
reuptake inhibitors: synthesis and 
structure-activity relationships. Bioorg 
Med Chem Lett. 2013; 23 (5): 1456-
1461. 
[14]. Marks DM, Shah MJ, Patkar AA, 
Masand PS, Park GY and Pae CU. 
Serotonin-norepinephrine reuptake 
inhibitors for pain control: premise and 
promise. Curr Neuropharmacol. 2009; 7 
(4): 331-336. 
[15]. Bannister K, Bee LA and Dickenson AH. 
Preclinical and early clinical 
investigations related to monoaminergic 
pain modulation. Neurotherapeutics. 
2009; 6 (4): 703-712. 
[16]. Mostert JP, Koch MW, Heerings M, 
Heersema DJ and De Keyser J. 
Therapeutic potential of fluoxetine in 
neurological disorders. CNS Neurosci 
Ther. 2008; 14 (2): 153-164. 
[17]. Tamiya J, Dyck B, Zhang M, Phan K, 
Fleck BA, Aparicio A, Jovic F, Tran JA, 
Vickers T, Grey J, Foster AC and Chen 
C. Identification of 1S, 2R-milnacipran 
analogs as potent norepinephrine and 
serotonin transporter inhibitors. 
Bioorganic & Medicinal Chemistry 
Letters. 2008; 18 (11): 3328-3332. 
[18]. Chappell AS, Ossanna MJ, Liu-Seifert 
H, Iyengar S, Skljarevski V, Li LC, 
Bennett RM and Collins H. Duloxetine, a 
centrally acting analgesic, in the 
treatment of patients with osteoarthritis 
knee pain: a 13-week, randomized, 
placebo-controlled trial. Pain. 2009; 146 
(3): 253-260. 
[19]. Collins SL, Moore RA, McQuayHj and 
Wiffen P. Antidepressants and 
anticonvulsants for diabetic neuropathy 
and postherpetic neuralgia: a 
quantitative systematic review. J Pain 
Symptom Manage. 2000; 20 (6): 449-
458. 
[20]. Solitar BM. Fibromyalgia: knowns, 
unknowns, and current treatment. Bull 
NYU Hosp Jt Dis. 2010; 68 (3): 157-161. 
[21]. Murty MSR, Solimabi and Kamat SY. 
Isolation of 2-benzoxazolinone from 
Acanthus ilicifolius. Indian J. Pharm. Sci. 
1984; 46: 218-219. 
[22]. Sam J and Plampin JN. Benzoxazoles: 
Potent Skeletal Muscle Relaxants. J 
Pharm Sci. 1964; 53: 538-544. 
[23]. Goekhan N, Aktay G and Erdogan H. 
Synthesis of some new pyridylethylated 
benzoxa(thia)zolinones with analgesic 
activity. Turk. J. Chem. 2004; 28: 123-
132. 
[24]. Dogruer DS, Unlu S, Sahin MF and 
Yesilada E. Anti-nociceptive and anti-
inflammatory activity of some (2-
benzoxazolone-3-yl and 2-
benzothiazolone-3-yl) acetic acid 
derivatives. Farmaco. 1998; 53 (1): 80-
84. 
[25]. Benson DA, Karsch-Mizrachi I, Lipman 
DJ, Ostell J and Wheeler DL. GenBank. 
Nucleic Acids Res. 2007; 35: D21-D25. 
[26]. Altschul SF, Madden TL, Schaffer AA, 
Zhang J, Zhang Z, Miller W and Lipman 
DJ. Gapped BLAST and PSI-BLAST: a 




PAGE | 395 |
 
new generation of protein database 
search programs. Nucleic Acids Res. 
1997; 25 (17): 3389-3402. 
[27]. Sali A and Blundell TL. Comparative 
protein modelling by satisfaction of 
spatial restraints. J Mol Biol. 1993; 234 
(3): 779-815. 
[28]. Wacker D, Wang C, Katritch V, Han 
GW, Huang XP, Vardy E, McCorvy JD, 
Jiang Y, Chu M, F. Y. Siu, W. Liu, H. E. 
Xu, V. Cherezov, B. L. Roth and R. C. 
Stevens. Structural features for 
functional selectivity at serotonin 
receptors. Science. 2013; 340 (6132): 
615-619. 
[29]. R. A. Laskowski, M. W. MacArthur, D. S. 
Moss and J. M. Thornton. PROCHECK: 
a program to check the stereochemical 
quality of protein structures. J. Appl. 
Crystallogr. 1993; 26: 283-291. 
[30]. Bolton EE, Wang Y, Thiessen PA and 
Bryant SH. PubChem: Integrated 
platform of small molecules and 
biological activities. Annu. Rep. Comput. 
Chem. 2008; 4: 217-241. 
[31]. Pettersen EF, Goddard TD, Huang CC, 
Couch GS, Greenblatt DM, Meng EC 
and Ferrin TE. UCSF Chimera--a 
visualization system for exploratory 
research and analysis. J Comput Chem. 
2004; 25 (13): 1605-1612. 
[32]. Berman HM, Westbrook J, Feng Z, 
Gilliland G, Bhat TN, Weissig H, 
Shindyalov IN and Bourne PE. The 
Protein Data Bank. Nucleic Acids Res. 
2000; 28: 235-242. 
[33]. Morris GM, Goodsell DS, Halliday RS, 
Huey R, Hart WE, Belew RK and Olson 
AJ. Automated docking using a 
Lamarckian genetic algorithm and an 
empirical binding free energy function. J. 
Comput. Chem. 1998; 19: 1639-1662. 
[34]. Seeliger D and de Groot BL. Ligand 
docking and binding site analysis with 
PyMOL and Autodock/Vina. J Comput 
Aided Mol Des. 2010; 24 (5): 417-422. 
[35]. Morris GM, Huey R, Lindstrom W, 
Sanner MF, Belew RK, Goodsell DS and 
Olson AJ. AutoDock4 and 
AutoDockTools4: Automated docking 
with selective receptor flexibility. J 
Comput Chem. 2009; 30 (16): 2785-
2791. 
[36]. Lill MA and Danielson ML. Computer-
aided drug design platform using 
PyMOL. J Comput Aided Mol Des. 2011; 
25 (1): 13-19. 
 
 
 
